| Autor: |
Siegal DM; Department of Medicine, University of Ottawa, Ontario, Canada (D.M.S.)., Forbes N; Department of Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada (N.F.)., Eikelboom J; Department of Medicine, McMaster University, Hamilton, Ontario, Canada (J.E., M.C.)., Beyer-Westendorf J; Department of Medicine I, Division of 'Thrombosis & Hemostasis,' University Hospital Dresden, Germany (J.B.-W.)., Cohen AT; Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Trust, London, United Kingdom (A.T.C.)., Xu L; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (L.X., S.J.C.)., Connolly SJ; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (L.X., S.J.C.)., Crowther M; Department of Medicine, McMaster University, Hamilton, Ontario, Canada (J.E., M.C.). |
| Abstrakt: |
Competing Interests: Disclosures Dr Siegal has received honoraria paid indirectly to her research institution from AstraZeneca, Bristol Meyers Squib-Pfizer, Nordic Biomarker, Roche, and Servier. She is supported by a Tier 2 Canada Research Chair. Dr Forbes has served as a consultant for Boston Scientific Corporation and has received research support and speaker fees for Pentax of America, Inc. Dr Eikelboom has received consulting fees/honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Pfizer, Janssen, Sanofi-Aventis, and Servier; and has received grants and in-kind support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Pfizer, Janssen, and Sanofi-Aventis. Dr Beyer-Westendorf has received personal funding or has sat on advisory boards for AstraZeneca, Bayer, Daiichi Sankyo, LEO Pharma, Mitsubishi, and Takeda, and has received institutional research funding from AstraZeneca, Bayer, Daiichi Sankyo, LEO Pharma, and Pfizer. Dr Cohen has received fees for serving on an adjudication committee from Boehringer Ingelheim and AbbVie; has received grant support and fees for serving on committees from Bristol Myers Squibb, Daiichi Sankyo, and Pfizer; has received consulting fees from Janssen, Portola Pharmaceuticals, and Ono Pharmaceuticals; and has received fees for serving on a steering committee and consulting fees from Bayer. Dr Connolly has received grant support and served as a consultant for Portola, Bristol Myers Squibb, Bayer, and Daiichi Sankyo; has served as a consultant for Javelin; and holds a patent (US 2010/0255000) and pending patent (US 2017/0369862 A1). Dr Crowther has received personal funding or has sat on advisory boards for AstraZeneca, Hemostasis Reference Laboratory, Syneos Health, and Eversana; has prepared educational materials and presented talks for Bayer, Pfizer, and CSL Behring; has participated in various medicolegal activities relating to thrombosis, anticoagulant drugs, or other aspects of hematologic practice; has worked with multiple for-profit and not-for-profit entities, such as UpToDate and medical communication companies; and holds the Leo Pharma Chair in Thromboembolism, which was endowed at McMaster University. Dr Xu has nothing to disclose. |
